Novartis, CH0012005267

Novartis stock heads into the open after a 0.98 percent gain

Published on 09/24/2026 at 08:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 23, 2026, Novartis stock stood at CHF 117.60 on SIX and gained 0.98 percent. The SMI fell 0.23 percent in the same session. Novartis signed a radioligand therapy licensing deal on September 22.

Pop-Art-Illustration einer DNA-Doppelhelix mit Kapsel in leuchtendem Halftone-Raster
Novartis AG CH0012005267 – Pop-Art-Comic mit stilisierter DNA-Helix und Kapsel im bunten Halftone-Raster, Illustration mit AI erstellt.

Novartis stock closed at CHF 117.60 on SIX on September 23, 2026, gaining 0.98 percent. The shares outperformed the SMI, which fell 0.23 percent to 13,921.72 points in the same session.

September 23, 2026 in numbers

Novartis AG (ISIN CH0012005267) opened at CHF 116.16 and reached an intraday high of CHF 118.50 on September 23, 2026. The close was CHF 14.?? below the 52-week high of CHF 132.68, while the 52-week low stood at CHF 96.80.

As MarketScreener reported on September 24, 2026, a US federal judge ruled for Novartis in litigation involving allegations concerning Entresto patent exclusivity. The company also agreed to license a preclinical radioligand therapy from Boomray Pharmaceuticals in a transaction with potential milestone payments of up to USD 900 million, according to BioWorld.

September 24, 2026 outlook

The Boomray licensing agreement remains a company-specific news item for September 24, 2026, as investors assess its potential milestone structure and oncology relevance. Swiss trading data for the next session will determine whether the previous session's 0.98 percent gain is extended or reversed.

Disclaimer...

en | CH0012005267 | NOVARTIS | boerse | 70174744 | bgmi